樂觀
$3.23
情境價格
$3.030
-0.222 (-7.34%)收盤時
KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.
KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

KORU Medical Presents Research at ONS Congress on Infusion Solutions

KORU Medical Systems Q1 2026 Earnings Call Highlights

Phreesia Shares Surge 5.1% Driven by Investor Optimism

KORU Medical Systems Secures EU Certification for Freedom60 Infusion Pump

KORU Medical Systems Q4 2025 Earnings Call Highlights
KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。